Biophytis S.A. (BPTS) |
|
0.4629 -0.012 (-2.55%)
|
01-27 15:59 |
|
Open: |
0.410801 |
Pre. Close: |
0.475 |
|
High:
|
0.4629 |
Low:
|
0.410801 |
|
Volume:
|
4,198 |
Market Cap:
|
9(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:43:02 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 0.63 One year: 0.73 |
| Support: |
Support1: 0.44 Support2: 0.37 |
| Resistance: |
Resistance1: 0.54 Resistance2: 0.63 |
| Pivot: |
0.47  |
| Moving Average: |
MA(5): 0.47 MA(20): 0.46
MA(100): 0.53 MA(250): 1.31 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 48.7 %D(3): 54.7 |
| RSI: |
RSI(14): 49.3 |
| 52-week: |
High: 5.9 Low: 0.34 |
| Average Vol(K): |
3-Month: 130 (K) 10-Days: 23 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BPTS ] has closed above bottom band by 32.0%. Bollinger Bands are 58.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.46 - 0.47 |
0.47 - 0.47 |
|
Low:
|
0.41 - 0.41 |
0.41 - 0.41 |
|
Close:
|
0.46 - 0.46 |
0.46 - 0.47 |
|
Company Description |
|
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France. |
Headline News |
Thu, 19 Jan 2023
Stock Market Rebounds Slightly to Close at 52,626.42 bpts - THISDAY Newspapers
Thu, 19 Jan 2023
2023-01-19 | NDAQ:BPTS | Press Release | Biophytis SA - Stockhouse
Tue, 17 Jan 2023
February 2023 - Building Power Training Series: City Budget 101 - City of Detroit
Thu, 12 Jan 2023
Biophytis To Take Appropriate Measures After Receiving Nasdaq ... - BioSpace
Thu, 05 Jan 2023
Biophytis Announces Its Participation in Two Major Investor ... - BioSpace
Thu, 03 Nov 2022
Biophytis (NASDAQ:BPTS) Stock Jumps on Positive COVID-19 Drug ... - TipRanks
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
20 (M) |
| Shares Float |
14 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0.3 (%) |
|
Shares Short
|
117 (K) |
|
Shares Short P.Month
|
153 (K) |
Stock Financials |
|
EPS
|
-2.78 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.41 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-52.9 |
|
Return on Equity (ttm)
|
-783.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.31 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-24 (M) |
|
Levered Free Cash Flow
|
-14 (M) |
Stock Valuations |
|
PE Ratio
|
-0.17 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.1 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.4 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
